The archetypal member of the Bcl-2 anti-apoptotic gatekeeper protein family is a well-studied drug target [1], validated in recent years by the clinical approval of Venetoclax (ABT-199) for the treatment of chronic lymphocytic leukemia, small lymphocytic lymphoma and acute myeloid leukemia [2]. The gene discussed is BCL2; the disease is B-cell chronic lymphocytic leukemia.